Cargando…

New developments in the management of advanced melanoma – role of pembrolizumab

Cancer immunotherapy is now recognized to be fundamental in modern oncology, because immune system recruitment may represent a powerful and innovative strategy in cancer therapy. Pembrolizumab, a highly selective humanized monoclonal antibody directly blocking the interaction between programmed cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Improta, Giuseppina, Leone, Isabella, Donia, Marco, Gieri, Stefania, Pelosi, Giuseppe, Fraggetta, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576895/
https://www.ncbi.nlm.nih.gov/pubmed/26396529
http://dx.doi.org/10.2147/OTT.S72823
_version_ 1782390917710217216
author Improta, Giuseppina
Leone, Isabella
Donia, Marco
Gieri, Stefania
Pelosi, Giuseppe
Fraggetta, Filippo
author_facet Improta, Giuseppina
Leone, Isabella
Donia, Marco
Gieri, Stefania
Pelosi, Giuseppe
Fraggetta, Filippo
author_sort Improta, Giuseppina
collection PubMed
description Cancer immunotherapy is now recognized to be fundamental in modern oncology, because immune system recruitment may represent a powerful and innovative strategy in cancer therapy. Pembrolizumab, a highly selective humanized monoclonal antibody directly blocking the interaction between programmed cell death-1 expressed by tumor-associated T-cells and its ligand programmed cell death-L1 present on tumor and stromal cells, was recently approved by US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma and disease progression upon ipilimumab and BRAF inhibitor. This review will focus on the clinical development and use of pembrolizumab in the clinical practice and in the management of advanced melanoma.
format Online
Article
Text
id pubmed-4576895
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45768952015-09-22 New developments in the management of advanced melanoma – role of pembrolizumab Improta, Giuseppina Leone, Isabella Donia, Marco Gieri, Stefania Pelosi, Giuseppe Fraggetta, Filippo Onco Targets Ther Review Cancer immunotherapy is now recognized to be fundamental in modern oncology, because immune system recruitment may represent a powerful and innovative strategy in cancer therapy. Pembrolizumab, a highly selective humanized monoclonal antibody directly blocking the interaction between programmed cell death-1 expressed by tumor-associated T-cells and its ligand programmed cell death-L1 present on tumor and stromal cells, was recently approved by US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma and disease progression upon ipilimumab and BRAF inhibitor. This review will focus on the clinical development and use of pembrolizumab in the clinical practice and in the management of advanced melanoma. Dove Medical Press 2015-09-14 /pmc/articles/PMC4576895/ /pubmed/26396529 http://dx.doi.org/10.2147/OTT.S72823 Text en © 2015 Improta et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Improta, Giuseppina
Leone, Isabella
Donia, Marco
Gieri, Stefania
Pelosi, Giuseppe
Fraggetta, Filippo
New developments in the management of advanced melanoma – role of pembrolizumab
title New developments in the management of advanced melanoma – role of pembrolizumab
title_full New developments in the management of advanced melanoma – role of pembrolizumab
title_fullStr New developments in the management of advanced melanoma – role of pembrolizumab
title_full_unstemmed New developments in the management of advanced melanoma – role of pembrolizumab
title_short New developments in the management of advanced melanoma – role of pembrolizumab
title_sort new developments in the management of advanced melanoma – role of pembrolizumab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576895/
https://www.ncbi.nlm.nih.gov/pubmed/26396529
http://dx.doi.org/10.2147/OTT.S72823
work_keys_str_mv AT improtagiuseppina newdevelopmentsinthemanagementofadvancedmelanomaroleofpembrolizumab
AT leoneisabella newdevelopmentsinthemanagementofadvancedmelanomaroleofpembrolizumab
AT doniamarco newdevelopmentsinthemanagementofadvancedmelanomaroleofpembrolizumab
AT gieristefania newdevelopmentsinthemanagementofadvancedmelanomaroleofpembrolizumab
AT pelosigiuseppe newdevelopmentsinthemanagementofadvancedmelanomaroleofpembrolizumab
AT fraggettafilippo newdevelopmentsinthemanagementofadvancedmelanomaroleofpembrolizumab